Capital Markets Event

Assura PLC
08 February 2024
 

8 February 2024

Assura plc

 

Capital markets event

 

 

Assura plc ("Assura"), the leading primary care property investor and developer, is today hosting a capital markets presentation and site tour for analysts and institutional investors.

 

Assura has identified several areas of emerging opportunities (NHS Trusts, private providers, mental health and Ireland) that are now becoming meaningful contributors to our portfolio, rental income and cash flow.

 

Members of the senior management team will present an update on our strategic approach to these emerging opportunities, outlining why we are targeting these areas alongside our existing GP medical centres and how our skills and capabilities mean we are well placed to become a market leader.

 

Specifically focused on the private market, the presentation will detail:

·      The state of the UK healthcare market and resultant increasing demand for high-quality, sustainable healthcare buildings in a community setting

·      Overview of trends and market opportunity in the private market segment

·      Assura's capabilities in capturing this opportunity; to complement its existing GP centre portfolio

·      An overview of recent private market development completions

·      Recent investments and asset enhancements within the mental health segment will also be highlighted

 

There will be a subsequent site tour to showcase Assura's recently completed, state-of-the-art cancer care facility in Guildford.

 

Jonathan Murphy, CEO of Assura, said: "There is significant demand for high-quality, sustainable healthcare buildings in a community setting to alleviate the considerable and growing pressures facing the NHS whilst improving the significantly underinvested existing estate. Each of these emerging areas is closely aligned with Assura's existing portfolio to relieve pressure on the health system; has attractive investment characteristics with a strong underlying tenant covenant and offers opportunities for future growth, which Assura is well placed to capture."

 

No new material trading information will be disclosed. A copy of the presentation is available on the Assura plc website at: https://www.assuraplc.com/investor-relations/reports-and-presentations

 

- ENDS -

 

 

Assura plc
David Purcell, Investor Relations Director

Tel: 0161 515 2043
Email: Investor@assura.co.uk

 

FGS Global

Gordon Simpson
Grace Whelan

 

Tel: 0207 251 3801
Email: Assura@fgsglobal.com

 

 

Notes to Editors

Assura plc is a national healthcare premises specialist and UK REIT based in Altrincham, UK - caring for more than 600 primary healthcare buildings, from which over six million patients are served.

 

A constituent of the FTSE 250 and the EPRA* indices, as at 30 September 2023, Assura's portfolio was valued at £2.7 billion.

 

At Assura, we BUILD for health. Assura builds better spaces for people and places, invests in skills and inspires new ways of working, and unlocks the power of design and innovation to deliver lasting impact for communities - aiming for six million people to have benefitted from improvements to and through its healthcare buildings by 2026. 

 

Assura is leading for a sustainable future, targeting net zero carbon across its portfolio by 2040.

 

Further information is available at www.assuraplc.com

 

*EPRA is a registered trademark of the European Public Real Estate Association.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Assura (AGR)
UK 100